How should I initiate Fosamax (alendronate) therapy, including dosing, required calcium and vitamin D supplementation, contraindications, monitoring, and duration of treatment?

Fosamax (Alendronate) Initiation and Management

For osteoporotic women, initiate alendronate 70 mg once weekly for 5 years, ensuring adequate calcium (1,200 mg/day total intake) and vitamin D supplementation, after correcting hypocalcemia and confirming the patient can comply with strict administration instructions. 1

Dosing Regimen

Standard dose: Alendronate 70 mg once weekly (oral tablet) 22

• Take with 6-8 ounces of plain water
• Must be taken at least 30 minutes before any food, drink, or other medication
• Patient must remain upright (standing or sitting) for at least 30 minutes after taking the medication 22

If a dose is missed: Take one tablet the morning after remembering, then return to the original weekly schedule. Never take two tablets on the same day 2

Calcium and Vitamin D Supplementation

Calcium requirements:

• Total daily intake: 1,200 mg/day for women ≥51 years (from all sources: diet + supplements) 3
• Average dietary intake is only ~600 mg/day, so most patients need supplementation 3
• Assess dietary calcium intake before prescribing supplements
• If supplementing, divide doses: no more than 500-600 mg per dose for optimal absorption 3
• Calcium carbonate (40% elemental calcium): Less expensive, requires fewer tablets, but needs gastric acid and should be taken with meals; may cause constipation
• Calcium citrate (21% elemental calcium): Better absorbed without food, less GI upset, but more expensive and requires more tablets 3

Vitamin D requirements:

• Ensure adequate vitamin D status before and during therapy 2
• Fosamax Plus D formulations contain 2,800 or 5,600 IU vitamin D3 weekly 2
• Patients at risk for vitamin D insufficiency may require higher supplementation doses 2
• Consider measuring 25-hydroxyvitamin D levels, especially in patients with malabsorption 2

Critical pre-treatment assessment:

• Hypocalcemia must be corrected before initiating alendronate 22
• Consider 24-hour urine calcium collection to assess calcium adequacy and absorption 3
• Treat other mineral metabolism disorders (e.g., vitamin D deficiency) before starting therapy 2

Absolute Contraindications

Do not prescribe alendronate if the patient has: 22

• Esophageal abnormalities that delay emptying (stricture, achalasia)
• Inability to stand or sit upright for at least 30 minutes
• Hypocalcemia (must correct first)
• Hypersensitivity to any component

Key Warnings and Monitoring

Upper GI complications: 22

• Alendronate can cause severe esophagitis, esophageal ulcers, erosions, and rarely perforation
• Instruct patients to STOP medication immediately and seek medical attention if they develop:
  • Dysphagia (difficulty swallowing)
  • Odynophagia (painful swallowing)
  • Retrosternal pain
  • New or worsening heartburn
• Use caution in patients with active upper GI problems (Barrett's esophagus, gastritis, ulcers)
• Patients who cannot comply with dosing instructions due to mental disability should not receive this medication without supervision

Osteonecrosis of the jaw (ONJ): 22

• Risk increases with duration of bisphosphonate exposure
• Higher risk with invasive dental procedures (extractions, implants)
• Consider discontinuing before invasive dental surgery
• Perform dental exam before initiating long-term therapy

Atypical femoral fractures:

• Rare but serious complication with long-term use
• Patients should report new thigh or groin pain

Musculoskeletal pain: 22

• Severe, occasionally incapacitating bone, joint, or muscle pain can occur
• Onset varies from one day to several months after starting
• Discontinue if severe symptoms develop

Duration of Treatment

Treat for 5 years, then reassess 1

• The American College of Physicians recommends 5 years of pharmacologic therapy for osteoporotic women 1
• Do not perform routine bone density monitoring during the 5-year treatment period 1
• After 5 years, reassess fracture risk to determine if continuation is needed

Evidence Quality

The recommendation for alendronate is based on strong, high-quality evidence showing reduction in hip and vertebral fractures in women with osteoporosis 1. Research demonstrates significant BMD increases at the lumbar spine (4.9%), femoral neck (2.4%), and total hip (3.0%) with good tolerability 4. The addition of calcium supplementation to alendronate in patients already consuming ≥800 mg dietary calcium does not significantly increase BMD beyond alendronate alone 5.

Clinical Pitfalls to Avoid

1. Do not prescribe without ensuring patient can follow administration instructions - Non-compliance with upright positioning and timing dramatically increases esophageal complications 22

2. Do not start therapy without correcting hypocalcemia - This is an absolute contraindication 22

3. Do not over-supplement calcium - Total intake should not exceed 1,500 mg/day; excessive calcium may be harmful 3

4. Do not use Fosamax Plus D alone to treat vitamin D deficiency (defined as 25-OH vitamin D <9 ng/mL) - Higher doses are needed 2

5. Do not routinely monitor BMD during treatment - This adds no benefit during the initial 5-year period 1